The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 18, 2023

Filed:

May. 25, 2018
Applicant:

The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US);

Inventors:

C. Garrison Fathman, Stanford, CA (US);

Luis R. Soares, Stanford, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/20 (2006.01); A61P 37/06 (2006.01); A61P 3/10 (2006.01); A61K 31/352 (2006.01); A61K 31/428 (2006.01); A61K 31/4365 (2006.01); A61K 31/4468 (2006.01); A61K 31/451 (2006.01); A61K 31/496 (2006.01); A61K 31/498 (2006.01); A61K 31/519 (2006.01); A61K 31/538 (2006.01); A61K 31/7064 (2006.01); A61K 31/7076 (2006.01);
U.S. Cl.
CPC ...
A61K 38/2013 (2013.01); A61K 31/352 (2013.01); A61K 31/428 (2013.01); A61K 31/4365 (2013.01); A61K 31/4468 (2013.01); A61K 31/451 (2013.01); A61K 31/496 (2013.01); A61K 31/498 (2013.01); A61K 31/519 (2013.01); A61K 31/538 (2013.01); A61K 31/7064 (2013.01); A61K 31/7076 (2013.01); A61P 3/10 (2018.01); A61P 37/06 (2018.01);
Abstract

Provided herein are methods and compositions for treating inflammatory disease by the administration, to a patient in need thereof, of an inhibitor of IL-2R desensitization in combination with a low dose of IL-2. A low dose of interleukin-2 (IL-2) is sufficient to stimulate regulatory T lymphocytes (Tregs) without substantially inducing effector T lymphocytes (Teffs). In some embodiments, the inhibitor of IL-2R desensitization is a small molecule or drug. Is some embodiments the inhibitor is a NEDD8 activating enzyme (NAE) inhibitor. In some embodiments a combination therapy provides for a synergistic effect, where the combination of the inhibitor of IL-2R desensitization and low dose IL-2 provides an effect that is greater than the sum of either the inhibitor or low dose IL-2 administered as a single agent.


Find Patent Forward Citations

Loading…